M&A Corner
Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment31 Jul 2023
Sanofi is set to acquire Qunol®, a prominent U.S. brand in the health and wellness sector. This transaction strengthens Sanofi’s... Continue Reading
|
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals.31 Jul 2023
Specialty pharmaceutical company Assertio Holdings and biopharmaceutical company Spectrum Pharmaceuticals have received approval from their stockholders for the proposed all-stock... Continue Reading
|
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement31 Jul 2023
Ayala Pharmaceuticals and BioSight have entered into a definitive merger agreement in an all-stock transaction. The combined company will operate... Continue Reading
|
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company31 Jul 2023
Carmell Therapeutics Corporation is set to acquire Axolotl Biologix, a regenerative medicine company focusing on soft tissue repair, aesthetics, and... Continue Reading
|
Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network31 Jul 2023
Headlands Research has acquired AMCR Institute, a clinical research site with expertise in metabolic, endocrine, and medical device research. Led... Continue Reading
|
FTC Lawsuit Holds Up IQVIA’s Advertising Acquisition of Propel Media31 Jul 2023
The acquisition of online marketing firm Propel Media by IQVIA is facing delays as the Federal Trade Commission (FTC) reviews... Continue Reading
|
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments31 Jul 2023
ABVC BioPharma, Inc. has signed a term sheet to advance a partnership with Zhonghui United Technology Group Co., Ltd. to... Continue Reading
|
Solar Biotech Acquires Noblegen31 Jul 2023
Solar Biotech Inc., a biomanufacturing solutions provider based in Norton, Virginia, has acquired Noblegen, a digital biology company in Canada.... Continue Reading
|
Eli Lilly Announces $2.4B Acquisition of Immunology Company Dice Therapeutics31 Jul 2023
Eli Lilly is set to acquire Dice Therapeutics for $2.4 billion in cash, providing a 40% premium on the smaller... Continue Reading
|
AstraZeneca, Pfizer Ink Potential $1B Gene Therapy Deal31 Jul 2023
AstraZeneca’s subsidiary, Alexion, is acquiring a portfolio of preclinical gene therapies and technologies from Pfizer in a deal worth up... Continue Reading
|